Otonomy Announces Change in Stock Exchange Listing
22 déc. 2022 07h53 HE
|
Otonomy, Inc.
SAN DIEGO, Dec. 22, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC) today announced that it received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (Nasdaq)...
Otonomy Provides Corporate Update
19 déc. 2022 16h53 HE
|
Otonomy, Inc.
SAN DIEGO, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC) today announced that the company’s board of directors, after considering strategic options, has approved and adopted a Plan...
Otonomy Reports Third Quarter 2022 Financial Results and Provides Corporate Update
10 nov. 2022 16h05 HE
|
Otonomy, Inc.
SAN DIEGO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today reported...
Otonomy Reports Results from Clinical Evaluation of OTO-413 Higher Doses in Patients with Hearing Loss
13 oct. 2022 07h30 HE
|
Otonomy, Inc.
Higher dose cohorts for OTO-413 demonstrated no clinically meaningful improvement for patients from baselineLack of activity compared to 0.3 mg dose evaluated in prior studies may be due to a complex...
Otonomy Reports Results from Phase 2 Clinical Trial of OTO-313 in Patients with Tinnitus
01 août 2022 07h30 HE
|
Otonomy, Inc.
OTO-313 demonstrated no clinically meaningful improvement versus placebo for primary and secondary endpoints across all timepointsCompany to discontinue development of OTO-313 and implement other...
Otonomy Reports Second Quarter 2022 Financial Results and Provides Corporate Update
25 juil. 2022 16h05 HE
|
Otonomy, Inc.
Top-line results for OTO-313 Phase 2 trial in tinnitus expected in August 2022; patient enrollment completed for clinical safety evaluation of higher and bilateral dosing of OTO-313 with top-line...
Otonomy to Report Second Quarter 2022 Financial Results and Provide Corporate Update
18 juil. 2022 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, July 18, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it...
Otonomy to Participate in the H.C. Wainwright Global Investment Conference
18 mai 2022 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, May 18, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced its...
Otonomy Announces OTO-825 Presentation at the American Society of Gene & Cell Therapy Annual Meeting
12 mai 2022 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, May 12, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the...
Otonomy Reports First Quarter 2022 Financial Results and Provides Corporate Update
09 mai 2022 16h04 HE
|
Otonomy, Inc.
Positive top-line results announced for OTO-413 Phase 2a in hearing loss; enrollment ongoing for higher dose evaluationOTO-313 Phase 2 trial in tinnitus fully enrolled with top-line results expected...